Sacituzumab Tirumotecan

Antibody–drug conjugate

Also known as SKB264, MK-2870

Approvedregulatory verdict

Evidence outlook

Approved: Unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer after... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Partial signal

Also in development:Non-Small Cell Lung Cancer · Phase 3 · investigational in the USHR+/HER2- Metastatic Breast Cancer · Phase 3 · investigational in the USOvarian Cancer · Phase 3 · investigational in the USCervical Cancer · Phase 3 · investigational in the USBladder Cancer · Phase 3 · investigational in the USEndometrial Cancer · Phase 3 · investigational in the US

Also approved (2)
CN
  • Unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer after prior endocrine therapy and at least one line of chemotherapy in the advanced settingpharmashots.com
  • EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC after progression on EGFR-TKI therapy and platinum-based chemotherapyseasidesignal.com
Product first approved 2025

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (27)
Bladder Cancer
NCT07829783 · Merck Sharp & Dohme LLC
2026-10-23 – 2036-09-25 · Bladder Cancer
What this study did
NCT07419295 · Merck Sharp & Dohme LLC
2026-04-23 – 2030-04-23 · Bladder Cancer
What this study did
Breast Cancer
NCT07628504 · Fudan University
2026-05-18 – 2035-03-30 · Adjuvant Drug Therapy
What this study did
NCT06279364 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2024-02-28 – 2028-12 · Triple Negative Breast Cancer
What this study did
Cervical Cancer
Endometrial Cancer
NCT06132958 · Merck Sharp & Dohme LLC
2023-12-06 – 2028-01-10 · Endometrial Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06966700 · Merck Sharp & Dohme LLC
2025-06-30 – 2034-12-29 · Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
What this study did
Non-Small Cell Lung Cancer
NCT06422143 · Merck Sharp & Dohme LLC
2024-06-10 – 2031-08-15 · Non-small Cell Lung Cancer, NSCLC
What this study did
NCT06074588 · Merck Sharp & Dohme LLC
2023-11-12 – 2030-03-11 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT06711900 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2024-10-30 – 2028-12 · Non-Small Cell Lung Cancer
What this study did
NCT06670196 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2024-11-27 – 2027-07 · Non-Small Cell Lung Cancer
What this study did
NCT06448312 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2024-06-07 – 2026-11 · Non-Small Cell Lung Cancer
What this study did
Ovarian Cancer
NCT07318558 · Merck Sharp & Dohme LLC
2026-02-16 – 2033-02-25 · Ovarian Neoplasms, Ovarian Cancer
What this study did
NCT06824467 · Merck Sharp & Dohme LLC
2025-04-09 – 2032-11-09 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
What this study did
Other / comorbidity
NCT06356311 · Merck Sharp & Dohme LLC
2024-05-03 – 2027-05-06 · Gastroesophageal Cancer
What this study did
Phase 2 (80)
Bladder Cancer
NCT07662863 · Fudan University
2026-07-15 – 2029-12-01 · Bladder Cancer, Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Peripheral Neuropathy
What this study did
Breast Cancer
NCT07109284 · West China Hospital
2025-09 – 2030-12 · ER+HER2- Breast Cancer
What this study did
NCT07371208 · Shanghai Jiao Tong University School of Medicine
2025-12-24 – 2030-08 · Breast Cancer
What this study did
NCT07458113 · Yale University
2026-08 – 2029-08 · Metastatic Triple Negative Breast Cancers
What this study did
NCT07244874 · Tianjin Medical University Cancer Institute and Hospital
2025-12-01 – 2029-07-30 · TNBC - Triple-Negative Breast Cancer, PD-L1 Positive
What this study did
NCT07182721 · Fudan University
2025-09-30 – 2029-02-01 · HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer, SKB264, Inetetamab
What this study did
NCT06849492 · Fudan University
2025-04-01 – 2028-12-31 · Advanced Triple Negative Breast Cancer
What this study did
NCT07054242 · Yantai Yuhuangding Hospital
2025-10-30 – 2028-06-30 · Neoadjuvant Therapy, Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer
What this study did
NCT07153965 · Tianjin Medical University Cancer Institute and Hospital
2025-09-01 – 2027-09-01 · Triple Negative Breast Cancer (TNBC), PD-L1 Positive
What this study did
NCT07007780 · Xijing Hospital
2025-08-20 – 2027-08-30 · Triple -Negative Breast Cancer
What this study did
Cervical Cancer
NCT07256236 · Fujian Cancer Hospital
2026-01-28 – 2028-12-15 · Cervical Cancer
What this study did
NCT07348861 · Zheng Min
2026-02-01 – 2028-01-01 · Cervical Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07471776 · Fudan University
2026-03-11 – 2029-03-11 · Metastatic Breast Cancer ( HER2 Negative)
What this study did
NCT07466927 · Fudan University
2026-03-15 – 2029-01-15 · HER2-negative Breast Cancer
What this study did
NCT07258108 · Sun Yat-sen University
2025-11-13 – 2028-12-30 · Breast Cancer
What this study did
NCT05445908 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2022-08-17 – 2026-07-31 · Triple-negative Breast Cancer and HR+/HER2- BC
What this study did
Non-Small Cell Lung Cancer
NCT07329322 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2026-03-30 – 2032-10-31 · Non-Small Cell Lung Cancer
What this study did
NCT06788912 · Merck Sharp & Dohme LLC
2025-03-20 – 2032-02-06 · Lung Neoplasm Malignant
What this study did
NCT07750704 · Guangdong Association of Clinical Trials
2026-09 – 2030-03 · ALK Positive Non-small Cell Lung Cancer
What this study did
NCT06706219 · Hunan Province Tumor Hospital
2026-05-10 – 2029-12-31 · Non Small Cell Lung Cancer (Stage III)
What this study did
NCT07854509 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2026-10-15 – 2029-12-30 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT07343479 · Zhejiang Cancer Hospital
2026-05-01 – 2029-12-20 · NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Gene Mutations, Brain Metastasis
What this study did
NCT07697586 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2026-08-07 – 2029-08 · NSCLC
What this study did
NCT07197008 · Li-kun Chen
2025-10-01 – 2028-12-30 · Lung Cancer
What this study did
NCT07375316 · Guangdong Association of Clinical Trials
2025-12-15 – 2028-12-30 · Non Small Cell Lung Cancer
What this study did
NCT07789444 · Xiaorong Dong
2026-08-30 – 2028-12-01 · Non-Small Cell Lung Cancer, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
What this study did
NCT07819578 · Shaodong Hong
2026-10-01 – 2028-12-01 · Non-Small Cell Lung Cancer
What this study did
NCT05816252 · Klus Pharma Inc.
2023-04-19 – 2028-08-31 · Non-small Cell Lung Cancer
What this study did
NCT07545213 · The Fourth Affiliated Hospital of Zhejiang University School of Medicine
2026-04-20 – 2028-08-15 · Non-small Cell Lung Cancer, EGFR Mutant Advanced Non-small Cell Lung Cancer
What this study did
NCT07244926 · Tianjin Medical University Cancer Institute and Hospital
2025-12 – 2028-06 · Lung Cancer
What this study did
NCT07670013 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-04-01 – 2028-06 · NSCLC
What this study did
NCT07703228 · Nanfang Hospital, Southern Medical University
2025-08-13 – 2028-03-13 · NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IIIB~IV, Second-line Therapy, Metastases
What this study did
NCT07438600 · Tianjin Medical University Cancer Institute and Hospital
2026-02-24 – 2028-02-28 · NSCLC (Non-small Cell Lung Cancer)
What this study did
NCT07548060 · Tianjin Medical University Cancer Institute and Hospital
2026-02-01 – 2028-01-22 · NSCLC Stage IV, EGFR Gene Mutation
What this study did
NCT06992739 · The First Affiliated Hospital of Xiamen University
2025-12-08 – 2027-12 · NSCLC (Advanced Non-small Cell Lung Cancer), EGFR, Myelosuppression
What this study did
NCT07193160 · Fudan University
2025-11-01 – 2027-05-30 · NSCLC (Non-small Cell Lung Cancer)
What this study did
NCT07323056 · Shanghai Pulmonary Hospital, Shanghai, China
2026-01-01 – 2026-12-01 · EGFR-mutant Non-small Cell Lung Cancer, Potentially Resectable
What this study did
NCT05351788 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2022-05-20 – 2026-12 · Non-small Cell Lung Cancer
What this study did
Ovarian Cancer
NCT07718854 · Tufts Medical Center
2026-09-12 – 2036-09 · Ovarian Clear Cell Carcinoma, Metastatic Ovarian Cancer, Recurrent Ovarian Clear Cell Adenocarcinoma
What this study did
NCT07314619 · The First Affiliated Hospital of Zhengzhou University
2025-12-30 – 2027-12-30 · Platinum-resistant Recurrent Ovarian Cancer (PROC)
What this study did
Other / comorbidity
NCT07511023 · M.D. Anderson Cancer Center
2026-09-25 – 2033-03-01 · Phase 2, Sacituzumab Tirumotecan, Refractory Metastatic, Unresectable Squamous, Cell Carcinoma of the Anus/ Rectum
What this study did
NCT07639086 · Virginia Commonwealth University
2026-08-31 – 2032-03-31 · Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)
What this study did
NCT07928193 · Latin American Cooperative Oncology Group
2027-03 – 2032-03 · Salivary Gland Cancers, Adenoid Cystic Carcinoma of the Salivary Gland
What this study did
NCT07804966 · Latin American Cooperative Oncology Group
2027-01 – 2032-01 · Vaginal Squamous Cell Carcinoma, Vulvar Squamous Cell Carcinoma
What this study did
NCT07785609 · Merck Sharp & Dohme LLC
2026-10-07 – 2031-09-30 · Advanced Solid Tumors, Malignant Neoplasm
What this study did
NCT07823270 · Hebei Medical University Fourth Hospital
2026-10 – 2030-12 · Esophageal Squamous Cell Carcinoma
What this study did
NCT07750353 · National Cancer Center, Japan
2027-02-01 – 2030-06 · Unresectable Thymic Carcinoma
What this study did
NCT07438626 · M.D. Anderson Cancer Center
2026-04-27 – 2030-02-01 · Phase II, Sacituzumab, Tirumotecan, SMARCB1-deficient Renal Medullary Carcinoma
What this study did
Phase 1/2 (14)
Bladder Cancer
NCT06637423 · Merck Sharp & Dohme LLC
2024-12-20 – 2026-09-30 · Non-Muscle Invasive Bladder Cancer
What this study did
Breast Cancer
NCT07139470 · Tianjin Medical University Cancer Institute and Hospital
2025-08-15 – 2027-10-15 · Triple Negative Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07738341 · Eddingpharm (Zhuhai) Co., Ltd.
2026-07-28 – 2030-08-01 · Breast Cancer (Locally Advanced or Metastatic)
What this study did
NCT04152499 · Klus Pharma Inc.
2020-02-28 – 2027-11-30 · Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07286149 · Merck Sharp & Dohme LLC
2026-04-30 – 2032-04-13 · Lung Neoplasm Malignant
What this study did
Other / comorbidity
NCT07908524 · Merck Sharp & Dohme LLC
2026-12-14 – 2032-06-29 · Metastatic Castration-resistant Prostate Cancer
What this study did
NCT06780111 · Merck Sharp & Dohme LLC
2025-07-30 – 2032-01-04 · Esophageal Squamous Cell Carcinoma
What this study did
NCT07586943 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2026-06-01 – 2030-12 · Advanced Solid Tumors
What this study did
NCT06445972 · Merck Sharp & Dohme LLC
2024-08-07 – 2030-08-08 · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
What this study did
NCT06428409 · Merck Sharp & Dohme LLC
2024-06-20 – 2029-10-16 · Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
What this study did
NCT06469944 · Merck Sharp & Dohme LLC
2024-09-20 – 2029-09-12 · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
What this study did
NCT07157956 · Convalife (Shanghai) Co., Ltd.
2025-09-10 – 2028-12-30 · Advanced Solid Tumor
What this study did
NCT06483334 · Merck Sharp & Dohme LLC
2024-07-17 – 2028-03-31 · Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
What this study did
Phase 1 (2)
Non-Small Cell Lung Cancer
NCT06049212 · Merck Sharp & Dohme LLC
2023-10-26 – 2028-01-29 · Non-small Cell Lung Cancer, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1(PDL1, PD-L1), Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
What this study did
NCT07702305 · Henan Cancer Hospital
2026-06-23 – 2027-12-31 · EGFR-TKI-resistant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT07068542 · Zhejiang Provincial People's Hospital
2025-07-01 – 2028-12-31 · Advanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Carcinoma
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Non-Small Cell Lung Cancer
NCT07895992 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-11-30 – 2030-12-30 · Non-squamous Non-small Cell Lung Cancer
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Other / comorbidity
NCT07778368 · Shanghai East Hospital
2026-09-01 – 2029-08-31 · Oral Squamous Cell Carcinoma (OSCC)
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, 2 of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sacituzumab Tirumotecan: this drugPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05870319: OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
APG-2449Phase 3Small moleculeFAK / ALK / ROS1not yet gradedNo reviewed efficacy summary in this indication
Beruzatatug PelitecanPhase 3Antibody–drug conjugateHER3not yet gradedNo reviewed efficacy summary in this indication
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4Weak signalNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported.
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
DostarlimabPhase 3Monoclonal antibodyPD-1Partial signal
NCT04655976: Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) missed
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
EnvafolimabPhase 3Monoclonal antibodyPD-L1Weak signal
NCT05068427: Primary endpoint ORR 6.7% (2/30); DCR 50% (15/30); median PFS 3.5 months
FamitinibPhase 3Small moleculec-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
NiraparibPhase 3Small moleculePARP1/2Partial signal
NCT04475939: Progression-free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) - Complete and Partial Response (CR/PR) Population (Up to 52 months): Niraparib + Pembrolizumab 5.55 Months (95% CI 4.14 to 8.28) vs Placebo + Pembrolizumab 5.55 Months (95% CI 4.21 to 7.16) missed
Nogapendekin Alfa Inbakicept (Anktiva)Phase 3Protein / enzyme therapeuticIL-15 superagonistnot yet gradedNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signal
NCT05865990: LMD cohort primary endpoint met: 3-month OS rate 65% (Kaplan-Meier estimate 69.6%, 95% CI 52.0-93.2, P < 0.001)
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Sacituzumab GovitecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05089734: EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant missed
Sotiburafusp AlfaPhase 3Multispecific antibodyPD-L1 / VEGFnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
UtidelonePhase 3Small moleculeTubulin / microtubulesPartial signal
NCT03693547: Primary endpoint ORR 15.4% (95% CI 4.4%-34.9%) in ITT (N = 26); 19.0% (95% CI 5.4%-41.9%) in per-protocol (N = 21)
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4Partial signal
NCT05984277: Dual primary endpoints (PFS and OS) not expected to be met: the IDMC concluded the volrustomig combination was unlikely to meet either, and AstraZeneca is discontinuing the trial (2026-08-17). missed
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 2Small moleculeHDACWeak signal
NCT05068427: Objective response rate: 6.7% (2/30); disease control rate 50%; median PFS 3.5 months (95% CI 1.9-5.5). Trial stopped early for futility against an expected ORR of 24%. missed
Denosumab (Xgeva)Phase 2Monoclonal antibodyRANKLPartial signalFeatured results are non-efficacy only in this race
Disitamab VedotinPhase 2Antibody–drug conjugateHER2Weak signalNo reviewed efficacy summary in this indication
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
NeratinibPhase 2Small moleculeEGFR/HER2Partial signal
NCT00266877: Objective response rate (primary endpoint): 3% in arm A (prior TKI, EGFR-mutation positive, n=91), 0% in arm B (prior TKI, EGFR wild-type, n=48), 0% in arm C (TKI-naive, n=28); 3 of 4 patients with exon 18 G719X EGFR mutation had a partial response missed
Notiretatug RezetecanPhase 2Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
Olvimulogene NanivacirepvecPhase 2Oncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
PrifetrastatPhase 2Small moleculeKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
Raludotatug DeruxtecanPhase 2Antibody–drug conjugateCDH6 (Cadherin-6)not yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 2Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab Drozuntecan
Phase 2(overall)
Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Tisotumab Vedotin Humax-Tf-Adc (Tivdak)Phase 2Antibody–drug conjugateTissue Factor (TF)Weak signalFeatured results are dose-finding only in this race
Tizetatug RezetecanPhase 2Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
TUB-040Phase 2Antibody–drug conjugateNaPi2b (sodium-dependent phosphate transporter, SLC34A2)not yet gradedNo reviewed efficacy summary in this indication
TucatinibPhase 2Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
UbamatamabPhase 2Monoclonal antibodyMUC16 x CD3not yet gradedNo reviewed efficacy summary in this indication
VisugromabPhase 2Monoclonal antibodyGDF-15not yet gradedNo reviewed efficacy summary in this indication
ALE.P02Phase 1/2Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
BL-M02D1Phase 1/2Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
CetrelimabPhase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Enfortumab VedotinPhase 1/2Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
LCB84
Phase 1/2(overall)
Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Puxitatug SamrotecanPhase 1/2Antibody–drug conjugateB7-H4not yet gradedNo reviewed efficacy summary in this indication
RezatapoptPhase 1/2Small moleculep53 reactivatornot yet gradedNo reviewed efficacy summary in this indication
TuvutromstatPhase 1/2Small moleculeMAT2AWeak signalNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
Ixotatug VedotinPhase 1Antibody–drug conjugateClaudin 6 (CLDN6)not yet gradedNo reviewed efficacy summary in this indication
MT-302
Phase 1(overall)
Gene therapy / editingTROP2not yet gradedNo reviewed efficacy summary in this indication
Sofetabart MipitecanPhase 1Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 113 furthest-along competitors are listed; 497 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(111 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Sacituzumab Tirumotecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (6)
November 2026 (1)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-11 · NCT06448312 · CT.gov ↗
What to watch
December 2026 (5)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT06711900 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-30 · NCT07108816 · CT.gov ↗
What to watch
Phase 2Selected Subjects With Advanced Solid TumorsActive not recruiting
Est. primary completion 2026-12-30 · NCT05631262 · CT.gov ↗
What to watch
Phase 2Adenoid Cystic Carcinoma of the Head and Neck, SBRT, Antibody-drug ConjugatesNot yet recruiting
Est. primary completion 2026-12-31 · NCT07579598 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT06081959 · CT.gov ↗
What to watch
2027 (38)
January 2027 (2)
Phase 2TNBC, Brain MetastasisRecruiting
Est. primary completion 2027-01 · NCT07623577 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)Not yet recruiting
Est. primary completion 2027-01-01 · NCT07561463 · CT.gov ↗
What to watch
February 2027 (2)
Phase 2Extensive-Stage Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-02-01 · NCT07388875 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-02-28 · NCT07438600 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-03 · NCT06992739 · CT.gov ↗
What to watch
April 2027 (2)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2027-04 · NCT06279364 · CT.gov ↗
What to watch
Phase 1/2Breast CancerNot yet recruiting
Est. primary completion 2027-04-15 · NCT07139470 · CT.gov ↗
What to watch
May 2027 (2)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-05 · NCT06670196 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-05-10 · NCT06074588 · CT.gov ↗
What to watch
June 2027 (4)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-06 · NCT07244926 · CT.gov ↗
What to watch
Phase 1/2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-06-11 · NCT05319730 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-06-20 · NCT07343479 · CT.gov ↗
What to watch
Phase 2Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant …Recruiting
Est. primary completion 2027-06-30 · NCT07179783 · CT.gov ↗
What to watch
July 2027 (7)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07 · NCT07071337 · CT.gov ↗
What to watch
Phase 2CholangiocarcinomaRecruiting
Est. primary completion 2027-07-01 · NCT07105852 · CT.gov ↗
What to watch
Phase 2Advanced Biliary Tract Cancer(BTC)Not yet recruiting
Est. primary completion 2027-07-01 · NCT07701122 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-07-01 · NCT07789444 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07-11 · NCT06312176 · CT.gov ↗
What to watch
Phase 2Neuroendocrine Neoplasms (Tumours)Not yet recruiting
Est. primary completion 2027-07-20 · NCT07077564 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07-30 · NCT07258108 · CT.gov ↗
What to watch
August 2027 (4)
Phase 2Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-08-01 · NCT07088211 · CT.gov ↗
What to watch
Phase 2Extensive-stage Small Cell Lung Cancer (ES-SCLC)Not yet recruiting
Est. primary completion 2027-08-31 · NCT07501169 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastro-esophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-08-31 · NCT07689292 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-31 · NCT07329322 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT07703228 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Solid TumorActive not recruiting
Est. primary completion 2027-11-30 · NCT05642780 · CT.gov ↗
What to watch
December 2027 (12)
Phase 2Advanced Biliary Tract CancersNot yet recruiting
Est. primary completion 2027-12 · NCT07729033 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12 · NCT07939204 · CT.gov ↗
What to watch
Phase 2Thymic Epithelial Tumors, Advanced Stage, Second-line TherapyNot yet recruiting
Est. primary completion 2027-12-22 · NCT07343453 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07197008 · CT.gov ↗
What to watch
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07314619 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07854509 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07702305 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT06049212 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT06849492 · CT.gov ↗
What to watch
Phase 2Recurrent or Metastatic Head and Neck CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07686588 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07811752 · CT.gov ↗
What to watch
Early phase / not applicableAdvanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer, Poorly Differentiated Thyroid CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07068542 · CT.gov ↗
What to watch
2028 (35)
January 2028 (9)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-01 · NCT07109284 · CT.gov ↗
What to watch
Phase 2Ovarian Epithelial CancerActive not recruiting
Est. primary completion 2028-01 · NCT07341100 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-01 · NCT07670013 · CT.gov ↗
What to watch
Phase 2Cervical CancerNot yet recruiting
Est. primary completion 2028-01-01 · NCT07348861 · CT.gov ↗
What to watch
Phase 3Endometrial CancerActive not recruiting
Est. primary completion 2028-01-10 · NCT06132958 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-01-15 · NCT07466927 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-01-22 · NCT07548060 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-01-25 · NCT06170788 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-01-30 · NCT07244874 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-02-15 · NCT07545213 · CT.gov ↗
What to watch
March 2028 (3)
Phase 2Penile Squamous Cell Carcinoma, Metastatic Penile Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2028-03 · NCT07815197 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-03-11 · NCT07471776 · CT.gov ↗
What to watch
Phase 1/2Metastatic Urothelial Carcinoma, Locally Advanced Urothelial CarcinomaActive not recruiting
Est. primary completion 2028-03-31 · NCT06483334 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Thymic CarcinomaRecruiting
Est. primary completion 2028-04 · NCT07324629 · CT.gov ↗
What to watch
May 2028 (1)
Phase 1/2Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal CancerRecruiting
Est. primary completion 2028-05-09 · NCT06445972 · CT.gov ↗
What to watch
June 2028 (4)
Phase 2Phase II, Sacituzumab, Tirumotecan, SMARCB1-deficient Renal Medullary CarcinomaRecruiting
Est. primary completion 2028-06-01 · NCT07438626 · CT.gov ↗
What to watch
Phase 3Cervical CancerActive not recruiting
Est. primary completion 2028-06-15 · NCT06459180 · CT.gov ↗
What to watch
Phase 2Cervical CancerRecruiting
Est. primary completion 2028-06-30 · NCT07256236 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-30 · NCT07375316 · CT.gov ↗
What to watch
August 2028 (5)
Phase 2Breast CancerRecruiting
Est. primary completion 2028-08 · NCT07371208 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-08 · NCT07458113 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-08 · NCT07697586 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorNot yet recruiting
Est. primary completion 2028-08-12 · NCT07157956 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-08-17 · NCT06305754 · CT.gov ↗
What to watch
September 2028 (3)
Phase 2ESCC, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC), GC/GEJCNot yet recruiting
Est. primary completion 2028-09-01 · NCT07701681 · CT.gov ↗
What to watch
Phase 2Recurrent or Metastatic MSI-H/dMMR Gynecological MalignanciesNot yet recruiting
Est. primary completion 2028-09-01 · NCT07738757 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-09-30 · NCT07182721 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Biliary Tract Cancer (BTC)Recruiting
Est. primary completion 2028-10 · NCT07850791 · CT.gov ↗
What to watch
Phase 2Recurrent Adenoid Cystic Carcinoma, Adenoid Cystic Carcinoma Metastatic, Papillary Thyroid CarcinomaNot yet recruiting
Est. primary completion 2028-10-31 · NCT07521670 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-11-30 · NCT06706219 · CT.gov ↗
What to watch
December 2028 (5)
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2028-12 · NCT07128693 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2028-12 · NCT07823270 · CT.gov ↗
What to watch
Phase 2Bladder CancerNot yet recruiting
Est. primary completion 2028-12-01 · NCT07662863 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-01 · NCT07819578 · CT.gov ↗
What to watch
Phase 2Advanced Small Bowel AdenocarcinomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07720258 · CT.gov ↗
What to watch
2029 (13)
January 2029 (2)
Phase 2Penile Squamous Cell Carcinoma (PSCC), Advanced Penile Cancer, Metastatic Penile Cancer, Locally Advanced Penile CancerNot yet recruiting
Est. primary completion 2029-01-01 · NCT07907861 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-01-12 · NCT06422143 · CT.gov ↗
What to watch
April 2029 (1)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2029-04-27 · NCT06824467 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Bladder CancerRecruiting
Est. primary completion 2029-07-27 · NCT07419295 · CT.gov ↗
What to watch
August 2029 (2)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-08-01 · NCT07738341 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-08-17 · NCT07286149 · CT.gov ↗
What to watch
September 2029 (2)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-09 · NCT07750704 · CT.gov ↗
What to watch
Phase 1/2Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal CancerRecruiting
Est. primary completion 2029-09-12 · NCT06469944 · CT.gov ↗
What to watch
October 2029 (2)
Phase 2Papillary Renal Carcinoma, Variant Histology Urothelial CarcinomaNot yet recruiting
Est. primary completion 2029-10 · NCT07716917 · CT.gov ↗
What to watch
Phase 1/2Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract CancerRecruiting
Est. primary completion 2029-10-16 · NCT06428409 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-11-15 · NCT07252739 · CT.gov ↗
What to watch
December 2029 (2)
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2029-12 · NCT07586943 · CT.gov ↗
What to watch
Phase 2Unresectable Thymic CarcinomaNot yet recruiting
Est. primary completion 2029-12 · NCT07750353 · CT.gov ↗
What to watch
2030 (7)
January 2030 (1)
Phase 2Ovarian Clear Cell CarcinomaNot yet recruiting
Est. primary completion 2030-01-31 · NCT07913568 · CT.gov ↗
What to watch
March 2030 (3)
Phase 2Vaginal Squamous Cell Carcinoma, Vulvar Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2030-03 · NCT07804966 · CT.gov ↗
What to watch
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2030-03-30 · NCT07628504 · CT.gov ↗
What to watch
Phase 2Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)Not yet recruiting
Est. primary completion 2030-03-31 · NCT07639086 · CT.gov ↗
What to watch
April 2030 (1)
Phase 2Salivary Gland Cancers, Adenoid Cystic Carcinoma of the Salivary GlandNot yet recruiting
Est. primary completion 2030-04 · NCT07928193 · CT.gov ↗
What to watch
May 2030 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2030-05-18 · NCT06841354 · CT.gov ↗
What to watch
December 2030 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2030-12-16 · NCT06393374 · CT.gov ↗
What to watch
2031 (4)
March 2031 (1)
Phase 2Phase 2, Sacituzumab Tirumotecan, Refractory Metastatic, Unresectable Squamous, Cell Carcinoma of the Anus/ RectumNot yet recruiting
Est. primary completion 2031-03-01 · NCT07511023 · CT.gov ↗
What to watch
September 2031 (1)
Phase 2Advanced Solid Tumors, Malignant NeoplasmRecruiting
Est. primary completion 2031-09-30 · NCT07785609 · CT.gov ↗
What to watch
October 2031 (1)
Phase 3Cervical CancerRecruiting
Est. primary completion 2031-10-29 · NCT07216703 · CT.gov ↗
What to watch
November 2031 (1)
Phase 3Bladder CancerRecruiting
Est. primary completion 2031-11-17 · NCT07829783 · CT.gov ↗
What to watch
2032 (4)
January 2032 (1)
Phase 1/2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2032-01-04 · NCT06780111 · CT.gov ↗
What to watch
February 2032 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2032-02-06 · NCT06788912 · CT.gov ↗
What to watch
May 2032 (1)
Phase 3Endometrial CancerRecruiting
Est. primary completion 2032-05-24 · NCT06952504 · CT.gov ↗
What to watch
June 2032 (1)
Phase 1/2Metastatic Castration-resistant Prostate CancerNot yet recruiting
Est. primary completion 2032-06-29 · NCT07908524 · CT.gov ↗
What to watch
2033 (2)
February 2033 (1)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2033-02-25 · NCT07318558 · CT.gov ↗
What to watch
March 2033 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2033-03-23 · NCT06966700 · CT.gov ↗
What to watch
2034 (1)
February 2034 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2034-02-21 · NCT06312137 · CT.gov ↗
What to watch
2036 (1)
September 2036 (1)
Phase 2Ovarian CancerRecruiting
Est. primary completion 2036-09 · NCT07718854 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 July 2026Filing acceptedNMPA accepts the new indication application for sac-TMT in first-line advanced TNBC
China, NMPA · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Source ↗